JP2023508938A5 - - Google Patents
Info
- Publication number
- JP2023508938A5 JP2023508938A5 JP2022538731A JP2022538731A JP2023508938A5 JP 2023508938 A5 JP2023508938 A5 JP 2023508938A5 JP 2022538731 A JP2022538731 A JP 2022538731A JP 2022538731 A JP2022538731 A JP 2022538731A JP 2023508938 A5 JP2023508938 A5 JP 2023508938A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025136672A JP2025186252A (ja) | 2019-12-26 | 2025-08-20 | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962953860P | 2019-12-26 | 2019-12-26 | |
| US62/953,860 | 2019-12-26 | ||
| PCT/US2020/067074 WO2021134045A1 (en) | 2019-12-26 | 2020-12-26 | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136672A Division JP2025186252A (ja) | 2019-12-26 | 2025-08-20 | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023508938A JP2023508938A (ja) | 2023-03-06 |
| JP2023508938A5 true JP2023508938A5 (https=) | 2024-01-25 |
| JPWO2021134045A5 JPWO2021134045A5 (https=) | 2024-01-25 |
| JP7736275B2 JP7736275B2 (ja) | 2025-09-09 |
Family
ID=76575158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538731A Active JP7736275B2 (ja) | 2019-12-26 | 2020-12-26 | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
| JP2025136672A Pending JP2025186252A (ja) | 2019-12-26 | 2025-08-20 | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025136672A Pending JP2025186252A (ja) | 2019-12-26 | 2025-08-20 | 抗ｃｄ３８治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230303710A1 (https=) |
| EP (1) | EP4081219A4 (https=) |
| JP (2) | JP7736275B2 (https=) |
| KR (1) | KR20220133198A (https=) |
| CN (1) | CN115335052A (https=) |
| AU (1) | AU2020412805A1 (https=) |
| CA (1) | CA3165475A1 (https=) |
| WO (1) | WO2021134045A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020411507A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| WO2023278778A1 (en) * | 2021-06-30 | 2023-01-05 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent |
| US20250009740A1 (en) * | 2021-11-22 | 2025-01-09 | Ohio State Innovation Foundation | Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions |
| WO2025202415A1 (en) * | 2024-03-28 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Dhodh inhibitors for use in the chronopharmacoligical treatment and prevention of obesity and obesity-related metabolic disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405237B2 (en) * | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| EP2567976B1 (en) * | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| WO2017037022A1 (en) * | 2015-09-01 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Compounds and methods useful for treating or preventing hematological cancers |
| EP3397625A4 (en) * | 2015-12-30 | 2019-12-25 | Agios Pharmaceuticals, Inc. | TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE |
| US10478497B2 (en) * | 2016-07-20 | 2019-11-19 | Hybrigenics S.A. | Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer |
| EP3661557B1 (en) * | 2017-07-31 | 2025-09-03 | Actinium Pharmaceuticals, Inc. | Treatments for a hematological malignancy |
| WO2019246603A1 (en) * | 2018-06-22 | 2019-12-26 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| AU2020411507A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| EP4081520A1 (en) * | 2019-12-26 | 2022-11-02 | Ohio State Innovation Foundation | Compositions for use in the inhibition of dihydroorotate dehydrogenase |
| US20230109418A1 (en) * | 2019-12-26 | 2023-04-06 | Ohio State Innovation Foundation | Compositions for use for the inhibition of dihydroorotate dehydrogenase |
-
2020
- 2020-12-26 WO PCT/US2020/067074 patent/WO2021134045A1/en not_active Ceased
- 2020-12-26 EP EP20905006.1A patent/EP4081219A4/en active Pending
- 2020-12-26 CN CN202080095284.0A patent/CN115335052A/zh active Pending
- 2020-12-26 US US17/789,187 patent/US20230303710A1/en active Pending
- 2020-12-26 AU AU2020412805A patent/AU2020412805A1/en active Pending
- 2020-12-26 JP JP2022538731A patent/JP7736275B2/ja active Active
- 2020-12-26 CA CA3165475A patent/CA3165475A1/en active Pending
- 2020-12-26 KR KR1020227025804A patent/KR20220133198A/ko active Pending
-
2025
- 2025-08-20 JP JP2025136672A patent/JP2025186252A/ja active Pending